AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28035016 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion (160 mg, range 110-200 mg in the 5 min before exercise)
Number of subjects: 0
Study 28035016 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol infusion
Number of subjects: 0
Study 28035016 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study 28035016 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol maintenance infusion (0.2 mg·kg total body mass-1·min-1)
Number of subjects: 0
Study 28035016 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion
Number of subjects: 0
Study 28035016 — intervention group
Group type: COMPARATOR
Intervention: Esmolol and saline infusion during epinephrine infusion
Number of subjects: 0
Study 26165688 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine or docetaxel (group A, n = 44)
Number of subjects: 88
Study 26165688 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide-vinorelbine-cisplatin (group B, n = 18)
Number of subjects: 88
Study 26165688 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin chemoradiotherapy (group C, n = 26)
Number of subjects: 88
Study 23475823 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ml of water
Number of subjects: 19
Study 23475823 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml of water
Number of subjects: 19
Study 21221002 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous continuous glucose monitoring
Number of subjects: 174
Study 18641196 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly folic acid supplementation (5000 or 2800 microg)
Number of subjects: 459
Study 18641196 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily folic acid supplementation (400 or 200 microg)
Number of subjects: 459
Study 18641196 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily and weekly iron, zinc, and vitamin B‐12 provided)
Number of subjects: 459
Study 16730617 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily
Number of subjects: 1045
Study 16730617 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg once daily
Number of subjects: 1045
Study 16730617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1045
Study 14594761 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 24
Study 14594761 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 24
Study 10716467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate treatment
Number of subjects: 100
Study 10716467 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study 9178918 — intervention group
Group type: COMPARATOR
Intervention: Breathing room air
Number of subjects: 65
Study 9178918 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing a hypoxic gas mixture
Number of subjects: 65
Study 9178918 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing a hypoxic gas mixture combined with intermittent breath holding
Number of subjects: 65
Study 1586061 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD-T (M. bovis)
Number of subjects: 192
Study 1586061 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD-B (M. intracellulare)
Number of subjects: 192
Study 1586061 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD-T
Number of subjects: 192
Study 1586061 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD-B
Number of subjects: 192
Study 1586061 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual testing (PPD-T and PPD-B)
Number of subjects: 192
Study 1586061 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD-B (bioequivalent to PPD-S)
Number of subjects: 192
Study 3985802 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled open drainage (gauze in plastic intestinal bag/surgical glove packing of abscesses; wound closure only to the degree needed to prevent evisceration)
Number of subjects: 31
Study 3985802 — intervention group
Group type: COMPARATOR
Intervention: Closed drainage (soft rubber or sump drains; complete fascial closure)
Number of subjects: 31
Study 3985802 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled open drainage
Number of subjects: 31
Study 30860943 — intervention group
Group type: EXPERIMENTAL
Intervention: PreProCare intervention (n = 372)
Number of subjects: 743
Study 30860943 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 371)
Number of subjects: 743
Study 30338680 — intervention group
Group type: EXPERIMENTAL
Intervention: Robuvit 300 mg/day
Number of subjects: 34
Study 30338680 — intervention group
Group type: COMPARATOR
Intervention: Standard Management (SM)
Number of subjects: 34
Study 27001568 — intervention group
Group type: EXPERIMENTAL
Intervention: Farletuzumab 1.25 mg/kg
Number of subjects: 1100
Study 27001568 — intervention group
Group type: EXPERIMENTAL
Intervention: Farletuzumab 2.5 mg/kg
Number of subjects: 1100
Study 27001568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1100
Study 27001568 — intervention group
Group type: EXPERIMENTAL
Intervention: Farletuzumab (above median exposure)
Number of subjects: 1100
Study 24418242 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich oil supplementation
Number of subjects: 0
Study 24418242 — intervention group
Group type: COMPARATOR
Intervention: OA-rich oil supplementation
Number of subjects: 0
Study 22607851 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ICD
Number of subjects: 700
Study 22607851 — intervention group
Group type: COMPARATOR
Intervention: Transvenous ICD
Number of subjects: 700
Study 21486536 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride (2mg/g)
Number of subjects: 20
Study 21486536 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (40 mg)
Number of subjects: 20
Study 17885255 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 hours of classroom instruction on stroke recognition and response
Number of subjects: 0
Study 17885255 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 15829836 — intervention group
Group type: EXPERIMENTAL
Intervention: Media campaign consisting of television and newspaper advertisements
Number of subjects: 0
Study 15829836 — intervention group
Group type: COMPARATOR
Intervention: Community-wide campaigns consisting of table tents, brochures, flyers, and posters
Number of subjects: 0
Study 12099160 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol (5 mg/day, increased to 10 mg/day if total cholesterol > 6.1 mmol/L after 6 months)
Number of subjects: 589
Study 12099160 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol
Number of subjects: 589
Study 12099160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 589
Study 10460554 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital capacity inhalational induction technique
Number of subjects: 60
Study 10460554 — intervention group
Group type: COMPARATOR
Intervention: Tidal breathing inhalational induction technique
Number of subjects: 60
Study 8546283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral oximetry monitoring
Number of subjects: 22
Study 2221412 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-min breathing of 100% O2
Number of subjects: 24
Study 2221412 — intervention group
Group type: COMPARATOR
Intervention: four-maximal-breaths of 100% O2
Number of subjects: 24
Study 833799 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring-loaded clips
Number of subjects: 300
Study 833799 — intervention group
Group type: COMPARATOR
Intervention: Electrocoagulation
Number of subjects: 300
Study 833799 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 300
Study 31055875 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening-detected prostate cancer (S-PCa)
Number of subjects: 1918
Study 31055875 — intervention group
Group type: COMPARATOR
Intervention: Clinically detected prostate cancer (C-PCa)
Number of subjects: 1918
Study 28099300 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate fixation
Number of subjects: 160
Study 28099300 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 160
Study 28099300 — intervention group
Group type: COMPARATOR
Intervention: Plate fixation and Nonoperative treatment
Number of subjects: 160
Study 26101115 — intervention group
Group type: EXPERIMENTAL
Intervention: NZ$5 monetary incentive
Number of subjects: 400
Study 22431208 — intervention group
Group type: EXPERIMENTAL
Intervention: PtCr-everolimus eluting stent (EES)
Number of subjects: 42
Study 22431208 — intervention group
Group type: COMPARATOR
Intervention: CoCr-everolimus eluting stent (EES)
Number of subjects: 42
Study 20584709 — intervention group
Group type: EXPERIMENTAL
Intervention: KERARINGS insertion followed by CXL 6 months later
Number of subjects: 10
Study 20584709 — intervention group
Group type: COMPARATOR
Intervention: KERARINGS insertion and CXL performed on the same day
Number of subjects: 10
Study 19901217 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichiasis surgery
Number of subjects: 439
Study 19901217 — intervention group
Group type: COMPARATOR
Intervention: No surgery (control)
Number of subjects: 439
Study 17914548 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with cardiovascular risk factors
Number of subjects: 1007
Study 12750100 — intervention group
Group type: EXPERIMENTAL
Intervention: argon green laser treatment (multiple 100‐micro m spots at least 750 micro m from the center of the fovea)
Number of subjects: 120
Study 12750100 — intervention group
Group type: COMPARATOR
Intervention: observation
Number of subjects: 120
Study 12750100 — intervention group
Group type: EXPERIMENTAL
Intervention: argon green laser treatment
Number of subjects: 120
Study 12750100 — intervention group
Group type: EXPERIMENTAL
Intervention: argon green laser treatment (higher-intensity laser burns)
Number of subjects: 120
Study 12750100 — intervention group
Group type: EXPERIMENTAL
Intervention: choroidal neovascularization in each treatment group
Number of subjects: 120
Study 11097147 — intervention group
Group type: EXPERIMENTAL
Intervention: DIC‐effervesc (50 mg diclofenac Na)
Number of subjects: 24
Study 11097147 — intervention group
Group type: COMPARATOR
Intervention: DIC‐enteric (50 mg diclofenac Na)
Number of subjects: 24
Study 9133184 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04 mg/kg neostigmine (group N25)
Number of subjects: 48
Study 9133184 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg edrophonium (group E25)
Number of subjects: 48
Study 9133184 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04 mg/kg neostigmine (group N5)
Number of subjects: 48
Study 9133184 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg edrophonium (group E5)
Number of subjects: 48
Study 9133184 — intervention group
Group type: COMPARATOR
Intervention: Control group (group SP)
Number of subjects: 48
Study 8442918 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (300 mg every 4 weeks)
Number of subjects: 331
Study 8442918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (160/800 mg 3 days a week)
Number of subjects: 331
Study 8442918 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone plus pyrimethamine (100 and 25 mg weekly)
Number of subjects: 331
Study 3529480 — intervention group
Group type: EXPERIMENTAL
Intervention: How to Stop Smoking booklet
Number of subjects: 1206
Study 3529480 — intervention group
Group type: COMPARATOR
Intervention: Control (normal way without booklet)
Number of subjects: 1206
Study 3529480 — intervention group
Group type: EXPERIMENTAL
Intervention: How to Stop Smoking booklet (at one clinic with no age imbalance)
Number of subjects: 1206
Study 3529480 — intervention group
Group type: COMPARATOR
Intervention: Control (at one clinic with no age imbalance)
Number of subjects: 1206
Study 31315861 — intervention group
Group type: EXPERIMENTAL
Intervention: rtfMRI-NFB training to increase activation of the ventral striatum
Number of subjects: 68
Study 31315861 — intervention group
Group type: EXPERIMENTAL
Intervention: rtfMRI-NFB training to increase activation of the anterior cingulate
Number of subjects: 68
Study 29604557 — intervention group
Group type: EXPERIMENTAL
Intervention: Acutrak 2 headless compression screws
Number of subjects: 18
Study 29604557 — intervention group
Group type: COMPARATOR
Intervention: Two parallel unicortical cancellous screws
Number of subjects: 18
Study 26920603 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI plus OMT
Number of subjects: 338
Study 26920603 — intervention group
Group type: COMPARATOR
Intervention: OMT alone
Number of subjects: 338
Study 24993763 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered Acceptance and Commitment Therapy (ACT) intervention, 8 sessions over 8 weeks
Number of subjects: 0
Study 24993763 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (offered ACT after 3-month follow-up)
Number of subjects: 0
Study 20880720 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG‐BF treatment
Number of subjects: 40
Study 20880720 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 40
Study 19171004 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrates (APCs) with a small quantity of autologous bone graft
Number of subjects: 18
Study 19171004 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest bone alone
Number of subjects: 18
Study 17242080 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 1, 1.25, or 1.5 MAC, age‐adjusted
Number of subjects: 54
Study 15625507 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass media community-wide physical activity intervention (paid advertisements, public relations, community participatory planning)
Number of subjects: 0
Study 15625507 — intervention group
Group type: COMPARATOR
Intervention: Comparison communities (control)
Number of subjects: 0
Study 12096292 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional care plus a nursing intervention (18-week, 10-contact nursing intervention utilizing problem-solving approaches)
Number of subjects: 113
Study 12096292 — intervention group
Group type: COMPARATOR
Intervention: Conventional care alone
Number of subjects: 113
Study 10440593 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA 12.5 mg tid
Number of subjects: 260
Study 10440593 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA 25 mg tid
Number of subjects: 260
Study 10440593 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 120 mg/day
Number of subjects: 260
Study 10440593 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA 75 mg/day with benzocaine gum 96 mg/day
Number of subjects: 260
Study 10440593 — intervention group
Group type: COMPARATOR
Intervention: Benzocaine gum 96 mg/day
Number of subjects: 260
Study 10440593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 7595979 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pendulum swing and weight-training
Number of subjects: 9
Study 7595979 — intervention group
Group type: COMPARATOR
Intervention: Weight-training only
Number of subjects: 9
Study 2368895 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 60
Study 2368895 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 60
Study 580509 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenformin and ethyloestrenol
Number of subjects: 314
Study 580509 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 314
Study 31533792 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 959
Study 31533792 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 959
Study 31533792 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy (COT)
Number of subjects: 959
Study 27910725 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiPatch medical device
Number of subjects: 1394
Study 27910725 — intervention group
Group type: COMPARATOR
Intervention: Medication use
Number of subjects: 1394
Study 25942434 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact Lens Sensor (CLS) - Triggerfish, Sensimed, Switzerland
Number of subjects: 33
Study 25942434 — intervention group
Group type: COMPARATOR
Intervention: Pneumatonometer (control)
Number of subjects: 33
Study 23567407 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 60
Study 23567407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21055479 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 257
Study 21055479 — intervention group
Group type: COMPARATOR
Intervention: Conscious sedation
Number of subjects: 257
Study 20301902 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking group
Number of subjects: 40
Study 20301902 — intervention group
Group type: COMPARATOR
Intervention: Tobacco abstinent group
Number of subjects: 40
Study 17275141 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (dietary counseling, liquid and multivitamin supplementation)
Number of subjects: 108
Study 17275141 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional intervention)
Number of subjects: 108
Study 15504857 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin alone (50 mg IV once daily)
Number of subjects: 10
Study 15504857 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin with nelfinavir (1,250 mg orally twice daily)
Number of subjects: 10
Study 15504857 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin with rifampin (600 mg orally once daily)
Number of subjects: 10
Study 15504857 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg orally once daily)
Number of subjects: 10
Study 15504857 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin (70 mg daily)
Number of subjects: 10
Study 11746323 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted Maximum Likelihood (REML) for continuous outcomes
Number of subjects: 0
Study 11746323 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimating Equations (EE) for continuous outcomes
Number of subjects: 0
Study 11746323 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted Pseudo-Likelihood (REPL) for binary outcomes
Number of subjects: 0
Study 11746323 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimating Equations (EE) for binary outcomes
Number of subjects: 0
Study 9013456 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive therapy (Ganciclovir administered intravenously for 21 days upon detection of CMV viremia)
Number of subjects: 36
Study 9013456 — intervention group
Group type: COMPARATOR
Intervention: Deferred therapy (Ganciclovir administered intravenously for 21 days upon detection of CMV viremia associated with a CMV syndrome)
Number of subjects: 36
Study 9013456 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive therapy (Ganciclovir use)
Number of subjects: 36
Study 9013456 — intervention group
Group type: COMPARATOR
Intervention: Deferred therapy (Ganciclovir use)
Number of subjects: 36
Study 9013456 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive therapy (CMV-associated charges)
Number of subjects: 36
Study 9013456 — intervention group
Group type: COMPARATOR
Intervention: Deferred therapy (CMV-associated charges)
Number of subjects: 36
Study 7843527 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 0
Study 7843527 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 0
Study 7843527 — intervention group
Group type: COMPARATOR
Intervention: FOBT
Number of subjects: 0
Study 7843527 — intervention group
Group type: COMPARATOR
Intervention: DRE
Number of subjects: 0
Study 7843527 — intervention group
Group type: COMPARATOR
Intervention: Genetic testing
Number of subjects: 0
Study 6374539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefoxitin
Number of subjects: 124
Study 6374539 — intervention group
Group type: COMPARATOR
Intervention: Intravenous normal saline
Number of subjects: 124
Study 6374539 — intervention group
Group type: COMPARATOR
Intervention: Uterine irrigation with cefoxitin
Number of subjects: 124
Study 6374539 — intervention group
Group type: COMPARATOR
Intervention: Uterine irrigation with normal saline
Number of subjects: 124
Study 30501475 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone health coaching intervention
Number of subjects: 31
Study 30501475 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 29735587 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pitavastatin (4 mg/d)
Number of subjects: 13054
Study 29735587 — intervention group
Group type: COMPARATOR
Intervention: Low-dose pitavastatin (1 mg/d)
Number of subjects: 13054
Study 26747128 — intervention group
Group type: EXPERIMENTAL
Intervention: modified constraint‐induced movement therapy (mCIMT) for 3 weeks
Number of subjects: 159
Study 26747128 — intervention group
Group type: COMPARATOR
Intervention: usual care for 3 weeks (control for mCIMT)
Number of subjects: 159
Study 26747128 — intervention group
Group type: EXPERIMENTAL
Intervention: electromyography‐triggered neuromuscular stimulation (EMG‐NMS) for 3 weeks
Number of subjects: 159
Study 26747128 — intervention group
Group type: COMPARATOR
Intervention: usual care for 3 weeks (control for EMG‐NMS)
Number of subjects: 159
Study 24488091 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional trabeculectomy
Number of subjects: 52
Study 24488091 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless trabeculectomy
Number of subjects: 52
Study 22978572 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete data collection
Number of subjects: 234
Study 22978572 — intervention group
Group type: COMPARATOR
Intervention: Complete data collection
Number of subjects: 234
Study 19666912 — intervention group
Group type: EXPERIMENTAL
Intervention: Early immunosuppressive therapy (cyclophosphamide for 12 months, and steroids)
Number of subjects: 26
Study 19666912 — intervention group
Group type: COMPARATOR
Intervention: Late immunosuppressive therapy (initiated when renal function deteriorated)
Number of subjects: 26
Study 17522939 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual working memory span scores for visual data link (RoboMemo exercise)
Number of subjects: 28
Study 17522939 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual working memory span scores in rotating data link (RoboMemo exercise)
Number of subjects: 28
Study 16479390 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave lithotripsy (ESWL)
Number of subjects: 35